Mylan settled a patent dispute with Roche Holding regarding a biosimilar version of Roche's successful breast cancer drug Herceptin, reports Reuters.
Here are four things to know.
1. Herceptin produced 6.78 billion Swiss francs ($6.7 billion) worth of sales in 2016. The treatment represents one of the world's most successful antibody drugs, according to Reuters.
2. Under the settlement, Mylan will earn global licenses for trastuzumab — its biosimilar version of Herceptin — and be able to launch the drug in new markets.
3. Mylan, which developed the drug with Biocon, already sells trastuzumab in 14 markets globally.
4. The drug is still pending regulatory approval in the U.S. and Europe.
More articles on supply chain:
Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night